Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Joint Clinical Trials Office Launched

Published: Friday, February 01, 2013
Last Updated: Friday, February 01, 2013
Bookmark and Share
Weill Cornell Medical College and NewYork-Presbyterian Hospital launched the new Joint Clinical Trials Office at NewYork-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medical College.

"The goal is to partner and invest in support of developing and expanding high-impact clinical trials that synergize with our missions of patient care, clinical and translational research and medical education," said Dr. John Leonard, director of the Office and associate dean for clinical research, the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology and professor of medicine at Weill Cornell.

The new Joint Clinical Trials Office at Weill Cornell and NewYork-Presbyterian will also collaborate with Weill Cornell's Clinical and Translational Science Center in support of investigators who are testing new treatments and providing new insights into disease. What Weill Cornell and NewYork-Presbyterian wants accomplish, Dr. Leonard said, is to increase the volume, quality and impact of clinical trials at all departments at the medical center while maximizing efficiencies and ensuring compliance.

"If we want to be first-rate in clinical research," he said, "we need to have an infrastructure and provide support that is consistent with our goals."

And that is to be the premier place for clinical trials designed by faculty and in collaboration with industry.

"There are a tremendous number of drugs out there, and we want our investigators to be playing a leadership role," Dr. Leonard said. "Industry is interested in institutions that can contribute both patients and expertise to the enterprise. We want to continue to develop and assist physician-scientists who are leaders in the field, who are innovative in their ways in bringing therapeutics forward. That is what industry wants and needs."

Increasingly, academic medical centers and industry are forging mutually beneficial partnerships, changing the paradigm of the two arms of biomedical research working independently of each other to achieve the same ends. A recent article in Nature Biotechnology notes that these partnerships produce a greater wealth of understanding about basic biology and disease pathogenesis that can result in more effective and safer drugs and treatments. Academia's strength in research and study design can further buttress industry's research and development programs that have in many cases thinned as a result of downsizing.

Weill Cornell and NewYork-Presbyterian are currently recruiting for top leadership positions in the office and establishing a steering committee to provide guidance and oversight, Dr. Leonard said. He expects the activities of the office to ramp up in earnest during the first half of 2013.

"Clinical trials are part of the culture of the institutions, and our faculty, staff and patients really want and expect to be part of clinical trials in every area of the Medical College," he said. "We hope that everybody involved will in one way or another contribute to this important enterprise."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Id1 Gene Interferes With Immune System
Uncovering new functions of a gene implicated in cancer growth opens new therapeutic possibilities.
Thursday, April 30, 2015
New Genomic Research Amends Earlier Triple Negative Breast Cancer Finding
Previously reported molecular finding unable to be validated.
Thursday, April 16, 2015
Advance in Regenerative Medicine Could Make Reprogrammed Cells Safer While Improving Their Function
Finding suggests the potential to repair a patients' organs using cells from ailing tissue.
Monday, August 05, 2013
Cocaine Vaccine Passes Key Testing Hurdle
New anti-cocaine vaccine research shows drug can't reach the brain, human clinical trials on the horizon.
Monday, May 13, 2013
New Method Developed to Expand Blood Stem Cells for Bone Marrow Transplant
Research shows fewer donor cells may be needed for transplantation and bone marrow banking may be possible.
Thursday, March 28, 2013
Researchers Solve the 3D Crystal Structure of One of the Most Important Human Proteins
Discovery of the atomic structure of a ligand-free g protein-coupled receptor (GPCR) will help design more effective drugs.
Thursday, February 28, 2013
Two Genes are Important Key to Regulating Immune Response
A research team at Weill Cornell Medical College has identified two genes that may be crucial to the production of an immune system cytokine called interleukin-10.
Wednesday, January 09, 2008
Stem Cells in Adult Testes Provide Alternative to Embryonic Stem Cells for Organ Regeneration
Isolation of specialized subsets of spermatogonial stem cells help generate a wide range of cell and tissue types, Weill Cornell team reports.
Friday, September 21, 2007
Weill Cornell Medical College Team Identifies Potential new Cancer Drug Target
Weill Cornell researchers have uncovered two new potential points of vulnerability on a key cancer-promoting protein, called XIAP.
Wednesday, June 27, 2007
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!